NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) — Petros Prescription drugs, Inc. (Petros, Nasdaq: PTPI), a number one supplier of therapeutics for males’s well being, right this moment declares it has entered right into a Sponsored Analysis Settlement (SRA) and an Choice Settlement with the Wellman Middle of Massachusetts Common Hospital (“Mass Common”), an affiliate of Harvard Medical Faculty. Beneath the settlement, researchers will consider incorporating using a tissue-specific oxygenation sensor with the aim of monitoring and understanding the success of Erectile System Remedy. Accompanying the Sponsored Analysis Settlement, Petros will enter into an Settlement for an possibility to barter an unique license of the tissue-specific oxygenation sensor inside particular human tissues. The Firm plans to use the know-how to probably improve its current erectile system remedy.
“We consider what Mass Common has developed is a really landmark achievement in quick and highly-targeted bio-sensor suggestions know-how,” mentioned Fady Boctor, Petros Prescription drugs’ President and Chief Business Officer. “This relationship with the Wellman Middle at Mass Common has the potential to empower the male affected person with progressive know-how to boost at-home remedy within the space of erectile dysfunction by demonstrating the effectiveness of exterior gadgets in a further non-invasive context.”
Each cellular and consumer-friendly, the sensor know-how is meant to supply the lads’s well being house the chance to boost at-home penile remedy with bio-sensor suggestions, which may inform each the affected person and the practitioner of ends in actual time.
About Petros Prescription drugs
Petros Prescription drugs is dedicated to the aim of changing into a world-leading specialised males’s well being firm by figuring out, growing, buying, and commercializing progressive therapeutics for males’s well being points together with, however not restricted to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial illnesses, Peyronie’s illness, hormone well being and substance use issues.
Cautionary Notice Relating to Ahead-Trying Statements
This press launch contains forward-looking statements inside the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Change Act of 1934, as amended. These forward-looking statements are based mostly upon Petros Prescription drugs, Inc.’s (“Petros,” “we,” “our,” “us” or the “Firm”) administration’s assumptions, expectations, projections, intentions and beliefs about future occasions. In some circumstances, predictive, future-tense or forward-looking phrases resembling “intend,” “develop,” “aim,” “plan,” “might,” “will,” “challenge,” “estimate,” “anticipate,” “consider,” “count on,” “proceed,” “potential,” “alternative,” “forecast,” “ought to” and related expressions, whether or not within the adverse or affirmative, are meant to determine forward-looking statements, however aren’t the unique technique of figuring out such statements. Precise outcomes and the timing of sure occasions and circumstances might differ materially from these described by the forward-looking statements because of dangers and uncertainties, together with, with out limitation, Petros’ potential to execute on its enterprise technique, together with its plans to develop and commercialize its product candidates; Petros’ potential to adjust to obligations as a public reporting firm; the flexibility of Petros to well timed and successfully implement controls and procedures required by Part 404 of the Sarbanes-Oxley Act of 2002; the chance that the monetary efficiency of Petros might not be as anticipated by the merger transactions that resulted within the Firm’s creation; dangers ensuing from Petros’ standing as an rising development firm, together with that lowered disclosure necessities might make shares of Petros widespread inventory much less engaging to traders; dangers associated to Petros’ potential to proceed as a going concern; dangers associated to Petros’ dependence on the commercialization of a single product, Stendra®, and on a single distributor thereof; dangers associated to Petros’ business provide settlement with Vivus; and dangers associated to Petros’ potential to acquire regulatory approvals for, or market acceptance of, any of its merchandise or product candidates. Further components that might trigger precise outcomes to vary materially from the outcomes anticipated in these forward-looking statements are contained within the Firm’s periodic experiences and in different filings that the Firm has filed, or might file, with the U.S. Securities and Change Fee (the “SEC”) underneath the headings “Danger Components” and “Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations” and elsewhere. The Firm cautions readers that the forward-looking statements included on this press launch symbolize our beliefs, expectations, estimates and assumptions solely as of the date of hereof and aren’t meant to provide any assurance as to future outcomes. New components emerge every so often, and it’s not attainable for us to foretell all of those components. Additional, the Firm can’t assess the impact of every such issue on our enterprise or the extent to which any issue, or mixture of things, might trigger precise outcomes to be materially totally different from these contained in any forward-looking assertion. Accordingly, you shouldn’t unduly depend on any forward-looking statements.
The Firm undertakes no obligation to replace or revise any forward-looking statements contained on this press launch, whether or not because of new info, future occasions, a change in our views or expectations or in any other case, besides as required by federal securities legal guidelines.